Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease

Therapeutic Drug Monitoring

Volumn 28, Issue 1, 2006, Pages 45-50

  Derijks, Luc J J ^a,b   Gilissen, Lennard P L ^c   Engels, Leopold G J B ^b   Bos, Laurens P ^b   Bus, Paul J ^d   Lohman, Joseph J H M ^b   Van Deventer, Sander J H ^e   Hommes, Daniel W ^e   Hooymans, Piet M ^b  

^a MÁXIMA MEDICAL CENTER   (Netherlands)

^b Sittard Geleen Heerlen   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LAURENTIUS HOSPITAL   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

6 thioguanine; Inflammatory bowel disease; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; TIOGUANINE; ANTINEOPLASTIC ANTIMETABOLITE;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; ENTERITIS; ERYTHEMA NODOSUM; FEMALE; FEVER; HEADACHE; HUMAN; MALAISE; MALE; NAUSEA; PRIORITY JOURNAL; STOMACH PAIN; BLOOD; CLINICAL TRIAL; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DRUG MONITORING; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THIOGUANINE;

EID: 33745513801     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000179839.71138.6d     Document Type: Article

References (31)

1. Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol. 1990;85:717-722.
2. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123:132-142.
3. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996;91:423-433.
4. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43:329-339.
5. Fairchild CR, Maybaum J, Kennedy KA. Concurrent unilateral chromatid damage and DNA strand breakage in response to 6-thioguanine treatment. Biochem Pharmacol. 1986;35:3533-3541.
6. + T lymphocytes. J Clin Invest. 2003;111:1133-1145.
7. Korelitz BI, Adler DJ, Mendelsohn RA, et al. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. Am J Gastroenterol. 1993;88:1198-1205.
8. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology. 1998;115:813-821.
9. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989;111:641-649.
10. Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993;34:1081-1085.
11. Dubinsky MC, Hassard PV, Seidman EG, et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis. 2001;7:181-189.
12. Derijks LJ, De Jong DJ, Gilissen LP, et al. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur J Gastroenterol Hepatol. 2003;15:63-67.
13. Herrlinger KR, Kreisel W, Schwab M, et al. 6-Thioguanine - efficacy and safety in chronic active Crohn's disease. Aliment Pharmacol Ther. 2003;17:503-508.
14. Bonaz B, Boitard J, Marteau P, et al. Thioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. Aliment Pharmacol Ther. 2003;18:401-408.
15. Dubinsky MC, Vasiliauskas EA, Singh H, et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology. 2003;125:298-303.
16. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705-713.
17. Derijks LJ, Gilissen LP, Engels LG, et al. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit. 2004;26:311-318.
18. Cuffari C, Seidman EG, Latour S, et al. Quantitation of 6-thioguanine in peripheral blood leukocyte DNA in Crohn's disease patients on maintenance 6-mercaptopurine therapy. Can J Physiol Pharmacol. 1996;74:580-585.
19. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med. 1997;126:608-614.
20. Herrlinger KR, Fellermann K, Fischer C, et al. Thioguanine-nucleotides do not predict efficacy of thioguanine in Crohn's disease. Aliment Pharmacol Ther. 2004;19:1269-1276.
21. Micromedex. http://healthcare.micromedex.com, 2004.
22. Deibert P, Dilger K, Fischer C, et al. High variation of thioguanine absorption in patients with chronic active Crohn's disease. Aliment Pharmacol Ther. 2003;18:183-189.
23. Brox LW, Birkett L, Belch A. Clinical pharmacology of oral 6-thioguanine in acute myelogenous leukemia. Cancer Chemother Pharmacol. 1981;6:35-38.
24. Lancaster DL, Patel N, Lennard L, et al. 6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations. Br J Clin Pharmacol. 2001;51:531-539.
25. Lennard L, Davies HA, Lilleyman JS. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br J Cancer. 1993;68:186-190.
26. McBride KL, Gilchrist GS, Smithson WA, et al. Severe 6-thioguanine- induced marrow aplasia in a child with acute lymphoblastic leukemia and inhibited thiopurine methyltransferase deficiency. J Pediatr Hematol Oncol. 2000;22:441-445.
27. Lancaster DL, Patel N, Lennard L, et al. Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia. Cancer Chemother Pharmacol. 2002;50:33-36.
28. Dervieux T, Blanco JG, Krynetski EY, et al. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res. 2001;61:5810-5816.
29. Geller SA, Dubinsky MC, Poordad FF, et al. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am J Surg Pathol. 2004;28:1204-1211.
30. de Jong DJ, Derijks LJ, Naber AH, et al. Safety of thiopurines in the treatment of inflammatory bowel disease. Scand J Gastroenterol Suppl. 2003;239:69-72.
31. Dubinsky MC, Feldman EJ, Abreu MT, et al. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol. 2003;98:1058-1063.